- Innovative approaches required to address the medicine access challenge
- Lessons to be learned from best practices in the field of pricing and reimbursement of medicines
- The value of list prices against the backdrop of external price referencing and managed entry
agreements. - Innovative policy options that need to be developed, agreed upon and implemented.
Moderator:
Andrew Stainthorpe, Head of Market Access, Oxford AHSN
Panellist:
Olga Katzelnik, Market Access Lead Europe/International, Regeneron
Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
Jörg Mahlich, Market Access & Government Affairs Lead, Miltenyi Biomedicine